A Phase 1, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 in Patients With Indolent Systemic Mastocytosis
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2017
At a glance
- Drugs AK 002 (Primary)
- Indications Systemic mastocytosis
- Focus Adverse reactions
- Sponsors Allakos
- 18 Dec 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2018.
- 18 Dec 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2018.
- 15 Sep 2016 According to Allakos media release, Frank Siebenhaar, M.D., of the Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, who, along with Professor Marcus Maurer, M.D., is a principal investigator for this study